Zacks: Concord Medical Services Hldg Ltd (CCM) Receives Consensus Rating of “Sell” from Analysts

Concord Medical Services Hldg Ltd (NYSE:CCM) has received a consensus broker rating score of 3.70 (Sell) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a sell rating.

Analysts have set a 12-month consensus price objective of $3.00 for the company and are expecting that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also assigned Concord Medical Services an industry rank of 114 out of 257 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised Concord Medical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 19th.

Shares of Concord Medical Services stock opened at $3.68 on Friday. Concord Medical Services has a one year low of $2.46 and a one year high of $4.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.10 and a quick ratio of 1.10.

Concord Medical Services Company Profile

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.

See Also: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Concord Medical Services (CCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply